A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis

Lebwohl, Mark; Siskin, Stewart B.; Epinette, Warren W.; Breneman, Debra; Funicella, Toni; Kalb, Robert E.; Moore, Jeffrey K.

doi:10.1016/s0190-9622(96)90349-7

Cited by 139 publications

(79 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since calcipotriol and corticosteroids work by different mechanisms [6, 7], superior efficacy may be achieved by combined use, and local irritation reported with calcipotriol may be alleviated by the anti-inflammatory action of the corticosteroid. Studies have shown that calcipotriol applied in the morning and corticosteroid in the evening is more effective than either calcipotriol twice daily or corticosteroid twice daily [8, 9, 10]. It would clearly be advantageous to have calcipotriol and a corticosteroid combined in the same treatment, to avoid the need for separate applications of each.…”

Section: Introductionmentioning

confidence: 99%

A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet<sup>TM</sup>) Is an Effective Once-Daily Treatment for Psoriasis vulgaris

et al. 2002

View full text Add to dashboard Cite

Background: Topical corticosteroids and calcipotriol have been used separately for many years to treat psoriasis. A new combination ointment has been formulated, which contains both calcipotriol and the corticosteroid betamethasone dipropionate. Objective: To compare the combination ointment with betamethasone dipropionate ointment, calcipotriol ointment and ointment vehicle in patients with psoriasis vulgaris. Methods: 1,603 patients were randomised to one of the 4 double-blind treatments used once daily for 4 weeks. Results: Themean percentage change in the PASI at the end of treatment was –71.3 (combination), –57.2 (betamethasone), –46.1 (calcipotriol) and –22.7 (vehicle). The mean difference of combination minus betamethasone was –14.2 (95% CI: –17.6 to –10.8, p < 0.001), of combination minus calcipotriol –25.3 (95% CI: –28.7 to –21.9, p < 0.001) and of combination minus vehicle –48.3 (95% CI: –53.2 to –43.4, p < 0.001). 6.0% of patients (combination) reported local adverse reactions compared to 4.9% (betamethasone), 11.4% (calcipotriol) and 13.6% (vehicle). Conclusion: Calcipotriol/betamethasone dipropionate combination ointment used once daily is well tolerated and more effective than either active constituent used alone.

show abstract

Section: Introductionmentioning

confidence: 99%

A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet<sup>TM</sup>) Is an Effective Once-Daily Treatment for Psoriasis vulgaris

et al. 2002

View full text Add to dashboard Cite

show abstract

“…The efficacy is as high as moderately potent steroids [4, 9]. The combination of calcipotriol with steroids further increases the effectiveness of the therapy, due to synergistic effects of the drugs [11,12,13,14,15]. The once daily application of calcipotriol and betamethasone dipropionate as a 2-compound product could offer an even higher effectiveness and cost-effectiveness compared to a twice daily application of the respective compounds, due to a higher compliance, enhanced synergistic effects and lower treatment costs.…”

Section: Discussionmentioning

confidence: 99%

“…Betamethasone dipropionate, a group III corticosteroid, acts via a glucocorticoid receptor and suppresses inflammation and hyperproliferation [10]. Several studies have shown that the combination of these 2 reagents has synergistic or additive effects and is better tolerated than either monotherapy [11,12,13,14,15]. In addition, the long-term safety of a fix calcipotriol/betamethasone dipropionate combination (Daivobet®/Dovobet®/Taclonex®) has been evaluated positively in several studies [16,17,18,19].…”

Section: Introductionmentioning

confidence: 99%

Cost-Effectiveness Model of Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Germany

et al. 2007

View full text Add to dashboard Cite

Background: Psoriasis vulgaris requires lifelong treatment associated with considerable health cost. Studies showed that a combination of a steroid and a vitamin D₃ analogue is more effective than both compounds in monotherapy. Objective: To determine the cost-effectiveness of a fix calcipotriol/betamethasone combination (Daivobet®/Dovobet®/Taclonex®) compared to a morning/evening non-fix calcipotriol/betamethasone combination in psoriasis treatment. Methods: A Markov model (discrete-time stochastic process based on transitions between health states) with 2 treatment arms (Daivobet/Dovobet/Taclonex vs. non-fix calcipotriol/betamethasone) over a 48-week time period was developed. The effectiveness criterion was the number of days with clearance or marked improvement. Clinical and health resource utilisation data were derived from randomised studies. Results: Treatment with Daivobet/Dovobet/Taclonex showed a higher cost-effectiveness compared to the non-fix combination, even when assuming a maximum compliance for the twice daily non-fix combination and varying the effectiveness of Daivobet/Dovobet/Taclonex by 10%. Conclusion: Psoriasis treatment with a fix calcipotriol/betamethasone combination is more cost-effective than a non-fix morning/evening combination.

show abstract

“…The study by Duweb et al showed better efficacy with occlusive calcipotriol applied for 6 weeks; twice-weekly occlusive calcipotriol ointment was as effective as the twice-daily application. [23] A study by Lebwohl M and Menter A et al, revealed that a high-potency topical corticosteroid in combination with vitamin D analog gave better efficacy, although it does not appear to be as effective as super potent corticosteroid used alone. [24,25] A combination with super potent topical clobetasol or halobetasol gave better results than with high potent topical betamethasone ointment.…”

Section: Combination Of Calcipotriol With Clobetasol Propionate Ointmmentioning

confidence: 99%

A Comparative Study of Efficacy of Hand Foot Psoralen-Ultraviolet a Therapy Versus Sequential Therapy of Topical Clobetasol Propionate With Topical Calcipotriol Ointment in Palmoplantar Psoriasis

Punniyaseelan¹,

Mathan²

2017

jemds

View full text Add to dashboard Cite

BACKGROUNDPalmoplantar psoriasis that accounts for 3% -4% of all psoriasis cases produces significant functional and social disability. Reduction of pain and improvement in the function of limbs are more important therapeutic goals than complete clearance. This prospective, randomised, controlled study was conducted in Coimbatore Medical College, a tertiary care centre in Tamilnadu. We conducted the study on 50 patients from September 2011 to November 2012. Aims and Objectives-The aims and objectives of the study was to compare the efficacy, to observe the reduction in percentage of psoriasis area and severity index score (PASI SCORE) above 50% and to observe the adverse effects in first 6 months and duration of remission in the next 6 months.

show abstract

A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis

Cited by 139 publications

References 4 publications

A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet<sup>TM</sup>) Is an Effective Once-Daily Treatment for Psoriasis vulgaris

A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet<sup>TM</sup>) Is an Effective Once-Daily Treatment for Psoriasis vulgaris

Cost-Effectiveness Model of Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Germany

A Comparative Study of Efficacy of Hand Foot Psoralen-Ultraviolet a Therapy Versus Sequential Therapy of Topical Clobetasol Propionate With Topical Calcipotriol Ointment in Palmoplantar Psoriasis

Contact Info

Product

Resources

About